|Awarded On||August 16, 2017|
|Title||Enhancing Immunotherapy of Pancreatic Cancer by Disrupting Mutant K-Ras Using CRISPR/Cas9|
|Award Mechanism||High Impact/High Risk|
|Principal Investigator/Program Director||Gang Bao|
Pancreatic cancer remains a major clinical challenge claiming more than 40,000 lives yearly in the US. Pancreatic ductal adenocarcinoma (PDAC), the most common type of pancreatic cancer that accounts for 95% of cases, is excruciatingly resistant to current chemo-radiation therap. Complete surgical removal of the tumor remains the only chance for cure, however 80-90% of PDAC patients are not eligible for curative surgical approaches at the time of clinical presentation. The overall 5-year survival is 5%. Unfortunately, many of the emerging immune-oncology approaches that have shown dramatic effects in certain solid cancers, such as antibodies against immune checkpoint proteins, have been inef...